Skip to main content

Table 1 Clinicopathological factors of the breast cancer patients with recurrent/metastatic lesions

From: Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions

Case ID Primary or relapse Age Primary systemic therapy Adjuvant therapy Histology pT pN Grade Ly V ER (%) PgR (%) HER2 Ki67 (%) Follow-up (months) Outcome
K18 breast primary 41 CPA, EPI, DTX, 5’DFUR X ICNOS 1a 0 2 0 1 0 0 0 76.0 23 DOD
local recurrence 42          < 1 0 1+ 70.5   
K20 breast primary 37 CPA, EPI PTX, TRA, TAM ICNOS 2 2a 3 3 1 60 0 3+ 57.1 60 DOD
pleural effusion 42          0 0 2 + (FISH +) 45.0   
K21 breast primary 66 CPA, EPI, EXE X, EXE ICNOS 4b 1a 2 1 2 90 10 1+ 39.5 63 DOD
local recurrence 68          100 70 1+ 22.3   
local recurrence 69          100 90 1+ 47.6   
K22 breast primary 63 no TAM ILC 1b 0 1 0 0 30 0 0 9.4 25 DOD
pleural effusion 65          0 < 1 0 24.8   
K23 breast primary 65 no no ICNOS 1a 0 1 0 0 95 80 1+ 11.8 92 LND
local recurrence 68          95 90 1+ 5.8   
K25 breast primary 35 CPA, EPI, DTX, 5’DFUR GEM ICNOS 2 1a 3 1 1 0 0 0 55.4 21 DOD
local recurrence 36          0 0 1+ 83.0   
K27 breast primary 55 CPA, EPI X ICNOS 3 0 3 3 0 5 2 1+ 68.2 7 DOD
local recurrence 55          0 0 0 87.0   
K28 breast primary 50 CPA, EPI, DTX, 5’DFUR CPA, EPI, X ICNOS 3 1a 3 3 2 0 0 1+ 86.8 50 DOD
local recurrence 51          0 0 1+ 57.4   
K30 breast primary 68 no 5FU, CPA, EPI ICNOS 1c 3b 3 1 0 0 0 0 80.2 12 DOD
pleural effusion 68          0 0 0 87.0   
pleural effusion #2 69          0 0 0 84.0   
K31 breast primary 47 CPA, EPI CPA, X ICNOS 1a 3a 3 1 0 0 0 0 65.4 28 DOD
pericardial effusion 48          0 0 0 36.6   
pleural effusion 49          0 0 0 58.4   
K32 breast primary 38 no CPA, EPI, TAM ICNOS 1c 1mi 2 2 1 80 2 1+ 37.5 83 DOD
lung metastasis 45          10 0 0 58.4   
  1. CPA cyclophosphamide, EPI epirubicin, DT docetaxel, 5’DFUR doxifluridine, 5FU 5 fluorouracil, TAM tamoxifen, X capecitabine, PTX paclitaxel, TRA trastuzumab,
  2. EXE exemestane, GEM gemcitabine, ICNOS invasive carcinoma of no special type, ILC invasive lobular carcinoma, na not available, DOD dead of disease, LND living without disease